Drugs / CS-1000
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02035085 | Jun 2014 → Jun 2022 | female breast carcinoma | Johns Hopkins University | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CS-1000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02035085 ↗ |
| Known as | CS-ATM DM Green | “Fluorescent CS-1000 (CS-ATM DM Green) labeled 87.0% ± 13.5% of CD34+ progenitor cells” PMID 26511652 ↗ Oct 2015 |
| Modality | Diagnostic / imaging agent | “the fluorinated ((19)F) agent CS-1000 as part of a first-in-human phase I trial (clinicaltrials.gov identifier NCT02035085) to track SVF cells with magnetic resonance imaging...” PMID 26511652 ↗ Oct 2015 |